Calcium Channel Blockers (Mechanism of Action)
Calcium Channel Blockers (Mechanism of Action) Read More »
Angiotensin receptor-neprilysin inhibitors (ARNI) is a new class of heart failure medications.
The first drug in this class is Entresto® (sacubitril/valsartan). It is a combination medication comprised of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan).
Sacubitril is a prodrug that inhibits neprilysin thus preventing it from breaking down natriuretic peptides. This mechanism leads to an increase in vasodilation and diuresis as levels of natriuretic peptides rise.
Valsartan directly blocks angiotensin II receptors inhibiting angiotensin II from binding onto the receptors and causing vasoconstriction and aldosterone release.
Entresto® (Sacubitril/Valsartan) Read More »